Redmile Group, LLC Fate Therapeutics Inc Transaction History
Redmile Group, LLC
- $952 Million
- Q1 2025
A detailed history of Redmile Group, LLC transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Redmile Group, LLC holds 12,872,946 shares of FATE stock, worth $14.8 Million. This represents 1.07% of its overall portfolio holdings.
Number of Shares
12,872,946
Previous 12,872,946
-0.0%
Holding current value
$14.8 Million
Previous $21.2 Million
52.12%
% of portfolio
1.07%
Previous 1.66%
Shares
13 transactions
Others Institutions Holding FATE
# of Institutions
144Shares Held
96.7MCall Options Held
56.7KPut Options Held
5.4K-
Vanguard Group Inc Valley Forge, PA10.3MShares$11.9 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$11.6 Million0.0% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY7.79MShares$8.96 Million0.04% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.29MShares$4.93 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY3.4MShares$3.91 Million0.0% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $112M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...